Biomarkers like FeNO and CRP should be routinely checked in patients with concurrent asthma and sleep apnea to assess disease outcomes, compare therapeutic approaches, and identify patients with increased risk factors. This evidence concerns the gene CRP and sleep apnea syndrome.